Kailera Therapeutics NASDAQ:KLRA said on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.
Reuters
Kailera's GLP-1 drug meets main goal of late-stage trials
- Sources
- Reuters
- Markets
- Stocks
- Active symbols
- NASDAQ:KLRA
- Language
- English (India)